Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07583251 · ClinicalTrials.gov registry record · Phase 1
Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
A Phase 1 study, sponsored by Pravat Mandal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT07583251 is a Phase 1 study that is actively recruiting participants, run by Pravat Mandal. The registered enrollment target is 9 participants.
The verdict
NCT07583251, a Phase 1 study, is actively recruiting participants, sponsored by Pravat Mandal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Interventions
- DRUG Gamma- Glutamylcysteine
- DRUG Gamma- Glutamylcusteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07583251
The ClinicalTrials.gov registry entry for NCT07583251 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pravat Mandal, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gamma- Glutamylcysteine is the first listed.
NCT07583251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07583251 about?
NCT07583251 is a clinical study titled "Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients". The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to i...
What is the current status of trial NCT07583251?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-06. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07583251?
The interventions under investigation include: Gamma- Glutamylcysteine (DRUG), Gamma- Glutamylcusteine (DRUG).
Who is sponsoring clinical trial NCT07583251?
This trial is sponsored by Pravat Mandal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.